Literature DB >> 11080374

Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C.

P C Hopkins1, R N Pike, S R Stone.   

Abstract

Protease cascades and their inhibitors are a common feature of many biological regulatory systems, and the various components of such cascades have been subjected to a long and concerted evolution. We present here evidence that in the coagulation cascade, the sequence of the protease-binding reactive-site loop of antithrombin has evolved such that the majority of its residues has been acquired not for the efficient inhibition of its target proteases, thrombin and factor Xa, but to avoid the inhibition of activated protein C (APC). We substituted residues of the reactive-site loop of antithrombin into alpha(1)-antitrypsin and tested the chimeras against thrombin, factor Xa, and APC. With respect to factor Xa and thrombin, the difference in association rate between the fastest and the slowest inhibitors was 5.5- and 88-fold, respectively. However, with respect to APC the difference was 12,500-fold. While most of the variation in the inhibition rates of thrombin could be accounted for by P2 Gly-to-Pro substitutions, for APC almost every residue had an effect on inhibition. In 22 of 25 direct comparisons of antitrypsin residues with antithrombin residues, either singly or in blocs, the antithrombin residues caused a decrease in the rate of inhibition of APC. The antithrombin residue Asn393, at position P'3, emerged as particularly important for avoiding the inhibition of APC, however, its 190-fold effect was seen only when in conjunction with antithrombin P7 to P'2 residues. Cooperative effects among residues of the reactive-site loop thus emerged as critical for restricting the activity of this sequence against APC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080374     DOI: 10.1007/s002390010114

Source DB:  PubMed          Journal:  J Mol Evol        ISSN: 0022-2844            Impact factor:   2.395


  11 in total

1.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

Review 2.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

Review 3.  Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  Biochem J       Date:  2016-08-01       Impact factor: 3.857

Review 4.  Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

Authors:  Steven T Olson; Benjamin Richard; Gonzalo Izaguirre; Sophia Schedin-Weiss; Peter G W Gettins
Journal:  Biochimie       Date:  2010-06-02       Impact factor: 4.079

5.  A reactive center loop-based prediction platform to enhance the design of therapeutic SERPINs.

Authors:  Wariya Sanrattana; Thibaud Sefiane; Simone Smits; Nadine D van Kleef; Marcel H Fens; Peter J Lenting; Coen Maas; Steven de Maat
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

Review 6.  Exosite determinants of serpin specificity.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

Review 7.  Therapeutic SERPINs: Improving on Nature.

Authors:  Coen Maas; Steven de Maat
Journal:  Front Cardiovasc Med       Date:  2021-03-31

8.  Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.

Authors:  Mostafa Hamada; Varsha Bhakta; Sara N Andres; William P Sheffield
Journal:  Front Cardiovasc Med       Date:  2021-03-19

9.  Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.

Authors:  Benjamin M Scott; Wadim L Matochko; Richard F Gierczak; Varsha Bhakta; Ratmir Derda; William P Sheffield
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

10.  Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.

Authors:  Leigh Ann Roddick; Varsha Bhakta; William P Sheffield
Journal:  BMC Biochem       Date:  2013-11-11       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.